Sylogent Launches Structured Data and Information Management Platform for Pharmaceutical Industry

Wednesday, August 3, 2016 Corporate News J E 4

NEWTOWN, Pa., Aug. 2, 2016 /PRNewswire/ -- Sylogent, a software and data services company, has announced the formal launch of SYQUENCE for the pharmaceutical industry.  The web-based system is designed to organize, standardize and automate the data necessary to produce critical information.

SYQUENCE is a flexible middleware tool that allows for structured data-driven processes to be implemented with minimal business interruptions. Integrated structured templates automatically create structured documents that maximize data consistency within a department and across the organization.  

"With more regulations, fewer resources, smaller budgets and shorter compliance timelines, the industry must begin to automate their information processes," stated Jack Yeager, CEO of Sylogent. "They cannot continue to manually process this heavily regulated information that ultimately must be consistent across the organization and public domain."

SYQUENCE has been deployed at several pharmaceutical companies to assist with study registration, clinical data disclosure and publication planning. The single Study Master Form automatically creates all of the required registration and data disclosure documents populated with shared data elements. The system also creates a publication study document that includes study data needed by publication teams.

"Too much critical data is being managed in spreadsheets, word documents and within emails on laptops and desktops. Pharma must operate in real time if they expect to satisfy growing compliance regulations," said Yeager.

To learn about SYQUENCE, visit or email

About Sylogent

Sylogent develops software that maximizes regulatory compliance, reduces operational costs and optimizes resource value. We leverage an integrated knowledge of process, data, technology and people to design solutions that deliver measurable results.

To learn about Sylogent, visit or email

This content was issued through the press release distribution service at For more info visit:

To view the original version on PR Newswire, visit:

SOURCE Sylogent



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Venous Thromboembolism Therapeutics Market Set to ...
Birner Dental Management Services, Inc. Schedules ...